Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccine
AssigneesMassachusetts Institute of Technology, The Board of Trustees of the Leland Stanford Junior University
InventorsKarl Dane WITTRUP, Darrell J. IRVINE, Cary Francis OPEL, Kelly Dare MOYNIHAN, Jennifer R. COCHRAN, Byron Hua KWAN
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating cancer with a combination of IL-2 (e.g., extended-PK IL-2), an integrin-binding-Fc fusion protein, and a cancer vaccine. The methods of the invention can be used to treat a broad range of cancer types.
Claims64
A method for treating a hyperproliferative disorder in a subject comprising administering to the subject a therapeutically effective amount of:
- a. interleukin (IL)-2;
- b. an integrin-binding-Fc fusion protein;
- and
- c. a cancer vaccine,
- wherein the integrin-binding-Fc fusion protein comprises (i) an integrin-binding polypeptide comprising an integrin-binding loop and a knottin polypeptide scaffold;
- and (ii) an immunoglobulin Fc domain, wherein the integrin-binding polypeptide is operably linked to the Fc domain.
A method for inhibiting growth and/or proliferation of tumor cells in a subject comprising administering to the subject an effective amount of an integrin-binding-Fc fusion protein, wherein the integrin-binding-Fc fusion protein comprises (i) an integrin-binding polypeptide comprising an integrin-binding loop and a knottin polypeptide scaffold;
- and (ii) an immunoglobulin Fc domain, wherein the integrin-binding polypeptide is operably linked to the Fc domain, and a cancer vaccine.
A method for inhibiting growth and/or proliferation of tumor cells in a subject comprising administering to the subject an effective amount of an integrin-binding-Fc fusion protein, wherein the integrin-binding-Fc fusion protein comprises (i) an integrin-binding polypeptide comprising an integrin-binding loop and a knottin polypeptide scaffold;
- and (ii) an immunoglobulin Fc domain, wherein the integrin-binding polypeptide is operably linked to the Fc domain, a cancer vaccine, and an immune checkpoint blocker.
A method for inhibiting growth and/or proliferation of tumor cells in a subject comprising administering to the subject an effective amount of an integrin-binding-Fc fusion protein, wherein the integrin-binding-Fc fusion protein comprises (i) an integrin-binding polypeptide comprising an integrin-binding loop and a knottin polypeptide scaffold;
- and (ii) an immunoglobulin Fc domain, wherein the integrin-binding polypeptide is operably linked to the Fc domain, a cancer vaccine, and an antagonist of VEGF.
Dependencies are inferred from the claim text.